The clinical research director of the UCSF Multiple Sclerosis Center offer his perspective on the 3 available agents for the treatment of patients with neuromyelitis optica spectrum disorder. [WATCH TIME: 2 minutes]
Disclaimer: The American Academy of Neurology requested that all attendees remain masked during the Annual Meeting. This interviewee voluntarily removed their mask for this interview.
WATCH TIME: 2 minutes
“We don’t have [high- and low-efficacy options], and the reason we don’t have that is because all 3 products are incredibly effective. They’re all great drugs, and that’s kind of amazing, right? We went from a state of having really nothing available to having 3 products that have knock-the-ball-out-of-the-park efficacy.”
Data presented at the 2022 American Academy of Neurology (AAN) Annual Meeting, April 2-7, in Seattle, Washington, from the phase 2/3 N-MOmentum trial (NCT02200770) in neuromyelitis optica spectrum disorder (NMOSD) suggested that the FDA-approved inebilizumab (Uplizna; Horizon Therapeutics) is effective for patients who have had both long-term disease and those who are newly diagnosed, with only a single relapse prior to treatment.1,2
These data add to an already robust efficacy profile for inebilizumab, which is the third of three agents to be approved for NMOSD, following eculizumab (Soliris; Alexion) and satralizumab (Enspryng; Genentech). Notably, all three therapies, while differing in route and frequency of administration as well as target, have been shown to be extremely effective in treating NMOSD relapses. Bruce Cree, MD, PhD, MAS, FAAN, professor of clinical neurology, University of California, San Francisco (USCF) Weill Institute for Neuroscience, and clinical research director, UCSF Multiple Sclerosis Center, sat down with NeurologyLive® at AAN 2022 to offer his perspective on how these agents stack up in the treatment of patients with NMOSD, ultimately sharing his satisfaction with the progress that’s been made in advancing the treatment landscape.